Imunomic Signs Joint Development Agreement with US-based Riplicat Bio
[Asia Economy Reporter Hyunseok Yoo] Immunomic Therapeutics, a US company acquired by HL Biopharma, announced on the 25th that it has signed a joint development agreement with Replicate Bioscience.
The main content of this agreement is to jointly develop vaccines for COVID-19 and therapeutic vaccines for cancers related to human papillomavirus (HPV) and Epstein-Barr virus (EBV) by combining Immunomic's immune vaccine platform technology UNITE with Replicate Bio's RNA therapeutic platform SynRGY.
Replicate Bioscience possesses the SynRGY technology, a platform technology for self-replicating RNA. It is developing treatments for cancer and infectious diseases by utilizing technology that enables immune cells to recognize drug-resistant cancers.
Separately from this agreement, Immunomic also participated in an equity investment in Replicate. Ji Hyuk Joo, Vice President of HL Biopharma, stated, "Through collaboration, we will rapidly expand Immunomic's core technologies into various fields, and by simultaneously acquiring shares of the partner company, we will ultimately expand HL Biopharma's bio-ecosystem across different sectors and regions."
William Hull, CEO of Immunomic Therapeutics, said, "The combination of the highly scalable UNITE platform and the RNA therapeutic platform technology SynRGY will lead to the development of more powerful therapeutics," adding, "We plan to further expand cooperation between the two companies, including the development of various new drug candidates."
Hot Picks Today
SpaceX Opens IPO Floodgates... Anthropic and OpenAI Push Valuations into the Trillions
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "From 119 Call to Hospital Transport"... Saving Sudden Cardiac Arrest Patients with AI and Video Calls
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Immunomic is currently preparing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for clinical trials to develop therapeutic vaccines alongside a Phase 2 clinical trial for cell therapy targeting glioblastoma. At the recent American Association for Cancer Research (AACR) 2020 annual meeting, it presented animal study results for ITI-3000, a Merkel cell carcinoma therapeutic, and is expanding indications based on the UNITE platform technology.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
